1 **Title:**
2 **Spectrum of innate and adaptive immune response to SARS-CoV-2 infection across**
3 **asymptomatic, mild and severe cases – a longitudinal cohort study**
4

Rita Carsetti[1,2]*, Salvatore Zaffina[3,4], Eva Piano Mortari[1#], Sara Terreri[1#], Francesco Corrente[2],
Claudia Capponi[2], Patrizia Palomba[2], Mattia Mirabella[2], Simona Cascioli[5], Paolo Palange[6], Ilaria
Cuccaro[6], Cinzia Milito[7], Alimuddin Zumla[8,9], Markus Maeurer[10,11], Vincenzo Camisa[3,4], Maria
Rosaria Vinci[3,4], Annapaola Santoro[3,4], Eleonora Cimini[12], Luisa Marchioni[13], Emanuele Nicastri[13],
Fabrizio Palmieri[13], Chiara Agrati[12], Giuseppe Ippolito[14], Ottavia Porzio[15,16], Carlo Concato[17],
Andrea Onetti Muda[18], Massimiliano Raponi[4], Concetta Quintarelli[19,20], Isabella Quinti[7], Franco
Locatelli[19,21]
12

13 <u>**Affiliations:**</u>
14

[1]B Cell Pathophysiology Unit, Immunology Research Area, Bambino Gesù Children's Hospital
IRCCS, Rome, Italy;
[2]Diagnostic Immunology Unit, Department of Laboratories, Bambino Gesù Children's Hospital,
IRCCS, Rome, Italy
[3]Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-
Technological Innovations Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[4]Health Directorate, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[5]Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[6]Department of Public Health and infectious diseases pulmonary division, Policlinico Umberto I
Hospital, Rome, Italy.
[7]Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
[8]Center for Clinical Microbiology, Division of Infection and Immunity, University College London,
London, United Kingdom
[9]NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United
Kingdom.
[10]Champalimaud Centre, Lisbon, Portugal
[11]Med Clinic, University of Mainz, Germany
[12]Cellular Immunology Laboratory, INMI L Spallanzani, IRCCS, Rome, Italy
[13]Clinical Department, INMI L Spallanzani, IRCCS, Rome, Italy
[14]Scientific Direction, INMI L Spallanzani, IRCCS, Rome, Italy
[15]Medical Laboratory Unit, Bambino Gesù Children's Hospital, IRCCS
[16]Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
[17]Virology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[18]Department of Laboratories, Bambino Gesù Children's Hospital, Rome, Italy
[19]Department of Hematology/Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[20]Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
[21]Department of Pediatrics, Sapienza, University of Rome, Rome, Italy
Lead contact
43

44 [#]These authors contributed equally to this work.
45

46 ***Corresponding author**: Dr. Rita Carsetti, B Cell Pathophysiology Unit, Immunology Research
47 Area, Diagnostic Immunology Unit, Department of Laboratories, Bambino Gesù Children Hospital,
48 Viale di San Paolo 15, 00146 Rome, Italy Fax: +39-06-72596822 e-mail: rita.carsetti@opbg.net

49
50
51

Funding:

This work was founded by the RF2013-02358960 grant from the Italian Ministry of Health.

Declaration of interests

The authors declare no competing interests

Summary: The ratio between monocytes and NK may represent a prognostic marker of disease

development in COVID-19. Individuals with asymptomatic SARS-CoV2 infection have a high

frequency of NK cells associated to a transient IgA response to the infection

Abstract:

Background: SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide

spectrum of clinical expression of SARS-CoV-2 illness suggests that individual immune responses

to SARS-CoV-2 play a crucial role in determining the clinical course after first infection.

Immunological studies have focussed on patients with moderate to severe disease, demonstrating

excessive inflammation in tissues and organ damage.

We have studied the individual response to SARS-CoV-2 of asympromatic, mild and severe

COVID-19 patients in order to investigate the role of innnate and adaptive immunity in determining

the clinical course after first infection.

Methods: To understand the basis of the protective immune response in COVID-19, we performed

a longitudinal follow-up analysis of innate and adaptive immunity in **64** adults with a spectrum of

clinical presentations: (**28** healthy SARS-CoV-2-negative contacts of COVID-19 cases; **20**

asymptomatic SARS-CoV-2-infected cases; **8** patients with mild COVID-19 disease and **8** cases of

severe COVID-19 disease).

Results: Our data show that high frequency of NK cells and early and transient increase of specific

IgA and, to a lower extent, IgG are associated to asymptomatic SARS-CoV-2 infection. By

contrast, monocyte expansion and high and persistent levels of IgA and IgG, produced relatively

late in the course of the infection, characterize severe disease. Modest increase of monocytes and

rapidly declining antibodies are detected in mild COVID-19.

Conclusions: The importance of innate NK cells and the short-lived antibody response of

asymptomatic individuals and patients with mild disease suggest that only severe COVID-19 may

result in protective memory established by the adaptive immune response.

Keywords: COVID-19, antibodies, NK, monocytes, adaptive immune system, innate immune

response.

Abbreviations: SARS-CoV-2: Severe Adult Respiratory Syndrome-Coronavirus-2, COVID-19:

Coronavirus Disease 2019, ACE2: Angiotensin Converting Enzyme-2, MBCs: memory B cells,

MLR: Monocyte-Lymphocyte ratio, NLR: Neutrophil-Lymphocyte ratio, MNKR: Monocyte-NK

ratio, IFN-γ: interferon-gamma, HLH: Hemophagocytic Lymphohistiocytosis, TGF-beta:

transforming growth factor-beta

Introduction

SARS-CoV-2 is a novel coronavirus, not encountered before by humans. Thus, everyone is susceptible to infection as the virus rapidly spreads in the current Coronavirus disease 2019 (COVID-19) pandemic. A wide spectrum of clinical expression of SARS-CoV-2 infection occurs, ranging from asymptomatic to mild upper respiratory tract illness, or moderate to severe disease with respiratory distress and multi-organ failure requiring intensive care and organ support[1]. This variability of disease severity suggests that the individual immune responses to SARS-CoV-2 play a crucial role in determining the clinical course after first infection. Understanding the pathogenesis of COVID-19 disease requires in-depth study of underlying immune responses[2].

In COVID-19, lymphopenia is common and correlates with severity of clinical disease[3]. Lymphopenia is caused by the reduction of both $CD4^+$ and $CD8^+$ T cells. Surviving T cells are functionally exhausted and reduced T-cell count predicts an unfavourable clinical course[4]. T cells able to react to SARS-CoV-2 peptides can be demonstrated in healthy individuals, probably because of a cross-reactivity with previous infections by other coronaviruses and are expanded in individuals convalescent from COVID-19[5].

Antibodies to SARS-CoV-2 are produced in large amounts in patients with severe disease, two-three weeks after the occurrence of first symptoms[6]. The role of antibodies in viral elimination is supported by the successful use of convalescent plasma in patients with severe COVID-19[7]. Neutralizing antibodies are directed against the Receptor Binding Domain contained in the S1 subunit of the Spike protein[8,9]. Whilst immune responses to novel antigens encountered for the first time, are first dominated by antibodies of IgM isotype, followed by IgG[10], the kinetics and protective or deleterious nature of the antibody responses to SARS-CoV-2 remains to be defined. A recent study indicated that the IgA response to SARS-CoV-2 may be rapid, strong and persistent[11]. The observation that patients with severe COVID-19 disease have very high antibody levels led to the suggestion that antibodies to SARS-CoV-2 may be damaging or ineffective rather than protective[12,13], as was reported from very sick patients with Middle East respiratory syndrome (MERS)[14].

Whilst immunological studies to date have focussed on patients with moderate to severe COVID-19 disease[15], studies from across the clinical spectrum are required to better understand immune responses to SARS-CoV-2 infection. We performed a longitudinal study of innate and adaptive immune populations in the peripheral blood of adults with asymptomatic SARS-CoV-2 infection, and those with mild and severe COVID-19 disease and their healthy contacts.

Methods:

Ethical approval

Ethical approval was obtained from the Medical Research and Ethics Committee at Sapienza,

University of Rome. The study was performed in accordance with the Good Clinical Practice

guidelines, the International Conference on Harmonization guidelines, and the most recent version

of the Declaration of Helsinki.

Study sites: 1) Bambino Gesù Children Hospital 2) Policlinico Umberto I Hospital.

Patients.

Sixty-four adult patients were enrolled in the study:

28 healthy controls: Contacts of SARS-CoV-2 confirmed cases who were confirmed as negative by

qPCR and were studied as control group;

20 asymptomatic cases (defined as contacts of COVID-19 cases but with no symptoms during the

duration of study time but tested positive for viral RNA). Asymptomatic patients were quarantined

and monitored for 14 days, and quarantine ended when two consecutive nasopharyngeal swabs

showed negative results[16];

8 patients with Mild COVID-19 disease (defined by positive SARS-CoV-2 nasopharyngeal swab

qPCR test, with symptoms such as fever, myalgia and fatigue without obvious chest HRCT findings

for COVID-19 did not require hospitalization);

8 cases of Severe COVID-19 disease from Policlinico Umberto I Hospital who were hospitalized

for respiratory disease with bilateral lung infiltrates at HRCT highly suggestive of COVID-19

interstitial pneumonia, and P/F $\geq$ 300 mmHg (defined as the ratio of arterial oxygen tension [PaO2]

to inspiratory oxygen fraction [FiO2]).

Clinical Characteristics.

Severe adult COVID-19 patients (8 patients) were older (mean age, 65 years, range 30-90) than

mild-symptoms adult COVID-19 patients (8 patients, mean age, 55.2 years, range 48-64). Sex ratio

with a prevalence of male patients was similar in the two groups (severe: M/F 6/2; mild: M/F 5/3).

During the study period, disease activity was regularly assessed, and COVID-19 patients continued

their therapies according to the standard of care. Four out of eight severe cases were treated with

anti-IL-6R monoclonal antibody (tocilizumab). All hospitalized COVID-19 patients were

discharged and none died. Twenty patients, grouped as SARS-CoV-2 asymptomatic patients had a

mean age of 40.4 (range 27-64) and a sex ratio (M/F) equal to 4/16. Twenty-eight contacts SARS-

CoV-2-negative had a mean age of 40.8 years (range 27-68) and an 8/20 M/F sex ratio

(**Supplementary Table 1**).

Flow-cytometry and antibodies

Four leukocyte profiling panels computing 7- to 9-surface marker antigens for monitoring the major
leukocyte subsets as well as characteristics of T-cell, B-cell, monocytes and NK cells subsets were
designed (**Supplementary Table S2**). Results of immune-profile of analyzed patients are reported
in **Supplementary Table 3-10**.
1 ml of total blood (EDTA) was incubated with the lysing solution Pharm Lyse (BD) to lyse red
blood cells. Then, cells were divided in four equal aliquots and stained with the appropriate
combination of fluorochrome-conjugated antibodies (**Table E1**) to identify immune cell subsets
according to standard techniques. For the staining of **Figure E7**, heparinized PBMCs of three
healthy donors were isolated by Ficoll Paque™ Plus 206 (Amersham Pharmacia Biotech) density-
gradient centrifugation. Cells were then stained with antibodies against CD19, CD24, CD27, CD38,
IgM, IgG, IgA and IgD (**Supplementary Table 1**). Cells were acquired on a BD FACSLyric™
(BD Biosciences). Data were analyzed with FlowJo ver. 10 (Treestar). Dead cells were excluded
from analysis by side/forward scatter gating.
185
Serum samples
Sera were obtained from the sixty-four patients included in the study. Some of the samples were
collected at different time points. Included in this study were 151 serum samples obtained from
subjects with available clinical records. In particular: forty-four sera from SARS-Cov-2 negative
contacts, fifty-one from SARS-Cov-2 asymptomatic patients, forty-one from COVID-19 mild
patients and fifteen from COVID-19 severe patients. All sera were kept on ice after collection and
then stored at -80°C.
193
Serological assays
The Euroimmun Anti-SARS-CoV-2 ELISA IgG and IgA assays (Euroimmun, Luebeck, Germany)
were performed on serum samples according to the manufacturer's instructions. The recommended
serum samples dilutions used were 1:100; in samples in which the IgA or IgG quantity was not
detectable (overflow), we used 1:1000, 1:3000, 1:6000, 1:25000 dilutions. These ELISA assays
provide a semi-quantitative *in vitro* determination of human antibodies of the immunoglobulin
classes IgG and IgA against the SARS-CoV-2. The microplate wells are coated with recombinant
S1 structural protein. The results are evaluated by calculation of the ratio between the extinction of
samples and the extinction of the calibrator. The ratio interpretation was as follows: <0.8 =
negative, ≥ 0.8 to < 1.1 = borderline, ≥ 1.1 = positive.
204
Statistical analysis

We performed the unpaired, two-tailed Mann-Whitney *U*-tests. A p≤0.05 was considered to be

statistically significant.

Results:

Innate immunity

The PBMCs of patients with asymptomatic infection, mild and severe disease and their healthy

contacts were compared. We correlated the immunological findings with the clinical course and

studied the dynamic changes of cells of innate and adaptive immune response.

By flow-cytometry, we confirmed that the Monocyte-Lymphocyte ratio (MLR) increases in

advanced COVID-19 cases, when T cells, normally representing the major lymphocyte population

in the peripheral blood, are reduced[15] (**Figure 1a and b**). Previous studies indicated that

neutrophils and macrophages infiltrate the lungs and are expanded in the peripheral blood of

Intensive Care Unit (ICU)-admitted patients[17]. The increase of circulating neutrophils and

monocytes, along with lymphopenia, explains why the Neutrophil-Lymphocyte ratio (NLR) and

MLR are significantly higher in patients with severe COVID-19 disease.

T-cell frequencies are preserved in asymptomatic individuals and in patients with mild disease.

Thus, in order to investigate whether other lymphocyte populations change in relationship to

monocytes, we excluded T cells from the first analysis (**Figure 1c and Supplementary Figure 1**).

Besides B cells discussed below, the CD3⁻ gate includes monocytes that can be distinguished by

their larger size measured by the high FCS, and NK cells. NK cells express the markers CD7

(**Figure 1c**) and CD56 **(Supplementary Figure 1s)**.

We found that the frequency of NK cells was reduced and that of monocytes increased in patients

with severe COVID-19. Similar alterations of NK and monocytes were observed in the group of

patients with mild disease (**Figure 1d and e**). For this reason, we calculated the Monocyte to NK

ratio (MNKR), which appeared to be altered not only in the severe cases, but also in patients with

mild disease (**Figure 1e**). The differences between asymptomatic, mild and severe COVID-19

remained significant when we included all the samples collected from the patients at different time

points (**Figure 2a**), suggesting that the reduction of NK and monocytes and the high MNKR was

not an incidental finding observed in a particular moment of the infection, but rather is a

characteristic of the disease. Each individual maintained his typical NK and Monocyte frequency

throughout the time of follow-up (**Figure 2b**). We confirmed the importance of the frequency of

NK cells by the retrospective analysis of 77 patients with severe COVID-19. Cases who did not

need ICU treatment had a significantly higher number of NK cells (CD56⁺ cells calculated in CD3⁻

lympho-monocyte gate) than ICU patients (**Figure 2c**). In addition, the percentage of NK cells

increased in those individuals who recovered from severe disease, whereas it remained low in

patients with fatal COVID-19 (**Figure 2d**). These results are corroborated by the observation that

ICU patients had lower perforin[+] NK cells compared to non-ICU patients[18].

CD16 expression allows to differentiate three types of CD14[+] monocytes (**Supplementary Figure**

2a and 3) in the peripheral blood, reflecting sequential stages of maturation and distinct

functions[19,20]. Classical monocytes are the precursors of the other types and play an important

role in the response to pathogens and in the resolution of inflammation. Intermediate monocytes

secrete inflammatory cytokines in response to Toll-Like Receptor (TLR) stimulation and expand in

the blood of patients with severe infections[21]. Non-classical monocytes contribute to the

resolution of inflammation and maintaining vascular homeostasis and endothelial integrity[22].

We found that non-classical monocytes were significantly reduced in patients with severe COVID-

19 when compared to SARS-CoV-2 negative contacts, SARS-CoV-2 positive asymptomatic and

also mild COVID-19 disease patients (**Supplementary Figure 2b**). Intermediate monocytes were

increased in the severe cases, but the difference reached statistically significance only when we

considered all samples collected for the study (**Supplementary Figure 2c**). As the progression

from the classical to intermediate stage is a dynamic step driven by infectious triggers[19], we

compared the monocyte phenotype in the same patients at different time points during the course of

the disease. Whereas intermediate monocytes were rare in the blood of contacts, asymptomatic and

mild disease patients at all time points, transient increases were observed in patients experiencing

severe disease (**Supplementary Figure 2d**).

In summary, we found that the MNKR reflects the clinical phenotype of the disease. Contact and

asymptomatic patients had either higher representation of NK cells or a similar frequency of NK

and monocytes (ratio around 1). The ratio was >1 in patients with mild disease and reached higher

values in the severe cases. Thus, the equilibrium between two cell types of the innate immune

system may play a role in the control of SARS-CoV-2 infection. Prevalence of NK cells is

associated to asymptomatic infection, while increased frequency of monocytes to severe disease.

Adaptive immunity

T and B cells play key roles in response to viral infections. CD8[+] T lymphocytes are crucial for the

limitation of viral spread through their cytotoxic function. CD4[+] T cells are indispensable for the

expansion of CD8[+] T cells and the generation of CD8[+] memory T cells[23]. In addition, CD4[+] T

cells are necessary for the germinal centre (GC) response and the production of memory B cells

(MBCs) and plasma cells[24].

A recent study reported that 82.1% of the severe COVID-19 cases had low circulating lymphocyte

counts because of the reduced frequency of CD3[+] T cells, both of CD4 and CD8 type[25]. In severe

COVID-19, not only the number of CD8$^+$ T cell declines but also their function is impaired, in

association with the increase of pro-inflammatory cytokines[18].

We observed an increase of activated, HLA-DR$^+$ CD4 T cells in patients with mild and severe

disease (**Figure 3a and b**). By contrast, HLA-DR$^+$ CD8 T cells were increased only in patients with

severe COVID-19 (**Figure 3 a and b**). This finding was confirmed when we included all samples in

the analysis (**Supplementary Figure 4**).

In a separate staining, we identified *naïve* and memory T cells, including central, effector and

terminally differentiated (TEMRA) memory T cells (**gating strategy in supplementary Figure 5**).

In the CD4$^+$ population of patients with mild and severe COVID-19, we found a reduction of recent

thymic emigrants (CD45RA$^+$CCR7$^+$CD31$^+$) and a consequent relative increase of CD31$^-$

CD45RA$^+$CCR7$^+$ T cells. No other significant modifications of the cell distribution were observed

and confirmed by the analysis of all patient samples (**Supplementary Figure 6**). In the CD8$^+$ T-cell

population, the most important change was the reduction of CD45RA$^+$CCR7$^+$ T cells, with modest

alterations of the CD31$^+$ and CD31$^-$ cell frequency. Total effector memory CD8$^+$ T cells were

increased only in asymptomatic cases (**Figure 4 and Supplementary Figure 6**), whereas in severe

disease, CD8$^+$ EM2 were increased and EM4 decreased. As reported before[5,26] CD8$^+$ TEMRA

were increased in patients with advanced disease (**Figure 4b and Supplementary Figure 6**).

Our data indicate that the circulating pool of T cells is not dramatically changed by SARS-COV-2

infection in asymptomatic individuals. In mild and severe cases, CD4$^+$ T cells express HLA-DR.

Activation of CD8$^+$ T cells could be only demonstrated in the severe cases and was associated to the

increase of highly cytotoxic EM2[27] and to the accumulation of exhausted TEMRA.

We identified the different B-cell populations in the peripheral blood by staining with a

combination of antibodies able to distinguish transitional, naïve, memory, atypical MBCs and

plasmablasts (**Figure 5a**). In the CD27$^+$ MBCs population, we separately analysed IgM$^+$ and

switched MBCs. The latter include IgG$^+$ MBCs and IgG$^-$ MBCs. Most of the IgG$^-$ B cells

correspond to IgA-expressing memory B and in minimal part to MBCs without detectable surface

immunoglobulin (**Supplementary Figure 7**). The most significant findings were the reduction of

total B cells and the increase of plasmablasts in the severe cases (**Figure 5b**). Among MBCs, we

found an increase of IgM$^+$ and a reduction of switched MBCs in asymptomatic and mild cases. In

patients with severe disease, IgM$^+$ MBCs were reduced and switched MBCs increased (**Figure 5c**),

with a significant expansion of the IgG$^-$ switched population. IgG$^+$ MBCs were reduced in the blood

of patients with mild disease (**Figure 5d**). For this reason, the ratio between IgG$^+$ and IgG$^-$ switched

MBCs, that is >1 in the SARS-Cov-2 negative contacts and asymptomatic individuals, is

significantly lower in patients with mild and severe COVID-19 indicating the expansion of MBCs

that do not express IgG and most probably express IgA (**Supplementary Figure 7**). All the

findings were confirmed by the cumulative analysis of all samples (**Supplementary Figure 8**).

B cells fight viruses by producing antibodies when they differentiate into circulating plasmablasts

or tissue–resident plasma cells. The final stages of differentiation can be reached by B cells in the

GCs, where either *naïve* or IgM[+] MBCs[28,29] acquire somatic mutations and are selected for their

increased affinity to the stimulating antigen[24]. T- and GC-independent antibody production is

efficiently and rapidly triggered by TLR-mediated stimulation of MBCs[30,31].

IgG and IgA antibodies directed against the S1 domain of the SARS-CoV-2 Spike protein were

measured in the entire study cohort. We found that antibodies are produced by all COVID-19

patients and also by SARS-CoV-2 positive asymptomatic individuals, with higher levels of IgG and

IgA being detected in the serum of patients with severe disease (**Figure 6a**) as reported

before[13,32].

In order to study the dynamic nature of the antibody response, we analysed its kinetics in 9

asymptomatic individuals, 8 patients with mild and 4 with severe disease. We found that

asymptomatic patients secrete high levels of S1-specific IgA early after diagnosis. IgA rapidly

declines and becomes undetectable after 5-7 weeks. IgG is low at most time points (**Figure 6b**).

The response of patients with mild disease has different kinetics, with IgG and IgA increasing later

and remaining relatively low, with few exceptions (**Figure 6c**). IgG and IgA are produced late in

patients with severe COVID-19, but in higher amounts[13,32]. IgA was always more abundant than

IgG (**Figure 6d**).

Antigen-specific IgA and IgG were undetectable in 2 patients with severe disease and in 1 with

mild disease. The inability to produce antibodies in isolated cases with severe and mild disease may

be due to individual genetic variation or age: pt34 was 83-year-old with a severe disease (1 single

sample was obtained), and pt14 was young but had a rapidly evolving severe disease (3 samples

were analysed at different time points), that improved with treatment. Pt11 (data not shown) with

mild disease was otherwise healthy, but had neurological symptoms and a positive nasopharyngeal

swab PCR lasting for 8 weeks (6 samples were evaluated).

The most interesting and intriguing aspect of the immunoglobulin study was the observation that

among the samples of asymptomatic individuals 17% (9 of 53 samples) were negative for IgG and

22.6% (12 of 53) were negative for IgA. This high percentage of negative samples cannot be

explained by individual variations. As serum antibody titers rapidly decline in asymptomatic

patients (**Figure 6b**), we correlated the level of SARS-CoV-2 specific antibody to the time from the

first positive nasopharyngeal swab. We found that six serum samples with non-detectable specific

IgA and IgG had been obtained from individuals diagnosed as positive for SARS-CoV-2 eight to

sixteen weeks prior to serum analysis (**Figure 6e-empty circles**). Of the other asymptomatic

individuals, we had multiple samples. In one case, IgA and IgG were undetectable in the first
sample obtained on same day of the first positive swab, but IgA and IgG rapidly increased in the
second sample at day 18 after the first positive swab. The other values below the detection threshold
refer to the late stages of the antibody kinetics from individuals with a previously detectable IgG
and IgA response.

In summary, we observed that asymptomatic patients have an early serum IgA response that may be
able to rapidly control SARS-CoV-2 in the respiratory mucosa, thus preventing a full adaptive
immune response. The lack of the early IgA burst may result in a longer persistence of the virus and
induction of the GC response in the local lymphoid tissue. The adaptive response becomes stronger
and probably geographically diffuse in the lymphoid tissue draining the severely damaged
respiratory epithelium in patients with severe disease.

Discussion

Individual immune responses play an important role in determining the clinical course of SARS-
CoV-2 infection in adults. Since the adaptive response requires time to build up after first encounter
with a novel virus, the first line immediate responders are NK cells and natural antibodies, key
components of innate immune system [33–37].

NK cells kill infected cells and produce IFN-ɣ with antiviral function[38]. 'Natural antibodies' are
antibodies that have a protective role in the early phases of the response independent of any
previous encounter with antigens [39–41]. In humans, natural antibodies are produced by innate
IgM$^+$ MBCs[31]. These antibodies, not yet been shaped by antigenic selection, carry few somatic
mutations[28] and have broad reactivity[42]. We recently suggested that these antibodies might
explain why most pediatric cases with laboratory-confirmed SARS-CoV-2 infection have either no
or mild symptoms and recover within 1–2 weeks[43]. Cross-reactive antibodies found in children
and adult never exposed to SARS-CoV-2[44] may correspond to natural antibodies. NK cells and
natural antibodies contain the infection, whilst adaptive immune response develop to generate
highly-specific memory T and B cells for clearing the virus and prevent re-infection[10].

In order to understand the basis of the immune response in COVID-19, we performed a global
analysis of innate and adaptive immunity in patients selected across the spectrum of disease
severity, ranging from SARS-CoV-2 positive asymptomatic individuals to patients with mild and
severe COVID-19.

Our data show that the balance between NK cells and monocytes is a sensitive indicator of the
individual reaction to the virus and is related to the clinical course of the disease. We found that
when NK cells are reduced, monocytes increase. Since each individual included in our study

maintained typical NK and monocyte frequency throughout the time of follow-up, we utilized the

ratio between peripheral blood monocyte and NK cells (MNKR) as a marker reflecting the clinical

phenotypes of the disease.

In patients with severe disease, monocytes expand and secrete inflammatory cytokines[45]. At this

point, inflammation may get out of control and cause immunopathology manifestations, supported

by the observation that SARS-CoV-2 infection of respiratory epithelial cells results in aberrant

transcriptional responses: antiviral IFN-I and III are not induced and, instead, a consistent

chemokines signature is established[46]. Migration of monocytes to the infected lungs scales up

inflammation resulting in further tissue damage[47,48]. Most of the described immune alterations

are reminiscent of Hemophagocytic Lymphohistiocytosis (HLH), a condition often related to

mutations of genes governing the cytotoxic lymphocyte machinery, where NK-cell deficiency leads

to chronic expansion and activation of monocytes and causes the life-threatening condition known

as cytokine storm[49–52]. As a consequence, therapeutic strategies counteracting the innate

immune failure at earlier stages of virus infection and counteracting excessive pro-inflammatory

cytokine levels have been successfully used in severe COVID-19[53,54]. Not only immune

"suppressive, yet also immune-modulatory therapies may be advantageous, depending on the

immunological situation of the patients[55].

We measured the specific IgG and IgA response to the S1 domain of the SARS-CoV-2 spike

protein in the serum of all patients and controls in our study at different time points. We found that

the clinical phenotypes of disease correspond to different antibody responses. We confirm that the

highest levels of IgG and also IgA are produced by patients with severe disease relatively late

during hospitalization[56]. Thus, a long and severe disease activates the adaptive immune response

and is associated with the production of anti-SARS-CoV-2 antibodies and MBCs[57].

In asymptomatic patients, we show an early burst of IgA that may rapidly and effectively eliminate

the virus in the respiratory mucosa and prevent a full adaptive immune reaction. Accordingly, IgG

is produced in low amounts and becomes undetectable after 6-8 weeks. An intermediate response is

observed in patients with mild disease without the early IgA peak and characterized by a late, but

modest IgG and IgA production, suggesting a minor adaptive immune response. Further studies are

necessary to establish whether specific memory persist and for how long after asymptomatic and

mild disease.

The particular antigen-specific IgA/IgG profile associated with clinical outcome may reflect

increased TGF-beta production induced by coronavirus-species[58]. Increased viral load may

increase TGF-beta production, that – if produced locally in the lung, facilitates neutrophil attraction

and induces specifically the isotype switch to IgA[59] **-** a situation that prompted the suggestion of
anti-TGF-beta directed immunotherapies[60,61].

Innate MBCs are increased in asymptomatic and mild disease. Innate MBCs produce natural
antibodies in response to TLR stimulation[30,39] but are also able to enter the GC where they
remodel their antibodies to increase their affinity[28,62]. IgM$^+$ MBCs are the precursors of most
IgA$^+$ and IgG$^+$ switched MBCs[62] and give rise to IgA$^+$ plasma cells at mucosal site[63]. We
speculate that the early IgA burst of asymptomatic individuals may derive from the rapid activation
of pre-existing innate or cross-reactive IgM$^+$ MBCs that switched to IgA in the respiratory
mucosa[11], as suggested also be the demonstration that moderate levels of IgM and IgA cross-
reactive to SARS-CoV-2 are present in the blood healthy individuals never exposed to the
infection[44]. In agreement with our hypothesis, neutralizing IgG MBCs isolated from COVID-19
patients may have no or very few somatic mutations[64]. In patients with severe COVID-19, IgM$^+$
MBCs are reduced and we observed an increase of IgG$^-$ MBCs probably expressing IgA (and thus
reflecting the immune reaction in the lymphoid tissue associated to the respiratory tree for local
protection. Circulating plasmablasts are increased only in the severe cases in correlation with their
high antibody levels especially of IgA isotype.

Our analysis of circulating T cells shows that in asymptomatic individuals, SARS-COV-2 infection
did not alter the T cell pool. In mild COVID-19, we only found an increase of activated CD4$^+$ T
cells, whereas in severe cases the activation of both CD4$^+$ and CD8$^+$ T cells might lead to clonal
exhaustion[5].

SARS-CoV-2 has evolved in bats, which control the infection through their innate immune system,
enriched for NK receptors and different types of INF type I genes[65]. Bats also produce antibodies
that are highly diverse thanks to a repertoire of VH, DH and JH fragments that is much larger than
that found in humans[66,67]. Antibodies do not undergo further improvement by introduction of
somatic mutation. Thus, constitutive IFN type I secretion and ready-to-use antibodies may control
viral infection in bats without the need of adaptive immune responses. For this reason,
coronaviruses and other viruses remain endemic in bats, without damaging the host[65].
Asymptomatic humans may behave like bats, controlling the infection thanks to NK cells and
antibodies. The adaptive immune response is strongest in patients with severe disease, following the
extensive tissue damage caused by the uncontrolled inflammatory reaction.

Our data has important implications for the control of clinical disease and for public health. In
COVID-19, it is indispensable to have prognostic markers early in the course of disease in order to
promptly choose appropriate treatments[68]. Although the MLR can be used as an indicator of
severe disease[69], the MNKR and the levels of specific IgA antibody in the serum may be more

sensible early markers of disease evolution.

Herd immunity to a virus is established when the large majority of the population becomes immune

and indirectly protects susceptible individuals. Memory T and B cells and long-lived plasma cells

generated by the adaptive immune response are the prerequisite for herd immunity, because specific

antibodies in the serum and immediately active memory cells prevent individual re-infection and

arrest pathogen transmission. Our data suggests that herd immunity to SARS-CoV-2 cannot be

achieved by natural infection. Social distancing and infection control will remain indispensable to

limit spread of SARS-CoV-2, until effective vaccines able to induce strong and long-lasting B- and

T-cell memory are available. Meanwhile, serology, especially when specific IgG is measured, may

be not a useful tool to support health policy measures[70]. We may fail to detect past mild

infections due to the rapid decline of IgG and we may under-evaluate persistence of viral circulation

because asymptomatic individuals respond to the virus with IgA.

References

1.   Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet **2020**;

2.   Maggi E, Canonica GW, Moretta L. COVID-19: unanswered questions on immune response
and pathogenesis. J Allergy Clin Immunol **2020**; Available at:
http://www.sciencedirect.com/science/article/pii/S009167492030631X.

3.   Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus
disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis
2020;

4.   Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients
With Coronavirus Disease 2019 (COVID-19). Front Immunol **2020**;

5.   Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype of SARS-CoV-2-specific T-cells in
COVID-19 patients with acute respiratory distress syndrome. medRxiv **2020**; Available at:
https://www.medrxiv.org/content/early/2020/04/18/2020.04.11.20062349.

6.   Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
COVID-19. Nat Med **2020**;

7.   Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-
19 patients. Proc Natl Acad Sci **2020**;

8.   Okba NMA, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-
19 patients. medRxiv **2020**;

9.   Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-
19 recovered patient cohort and their implications. medRxiv **2020**;

10.   Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol **2015**; 15:149–59.
483   Available at: http://www.ncbi.nlm.nih.gov/pubmed/25677494.

484   11.   Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-
485   CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta **2020**;

486   12.   Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte
487   ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv
488   **2020**;

489   13.   Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel
490   coronavirus disease 2019. Clin Infect Dis **2020**;

491   14.   Wan Y, Shang J, Sun S, et al. Molecular Mechanism for Antibody-Dependent Enhancement
492   of Coronavirus Entry. J Virol **2019**;

493   15.   He R, Lu Z, Zhang L, et al. The clinical course and its correlated immune status in COVID-
494   19 pneumonia. J Clin Virol **2020**;

495   16.   Wang Y, Kang H, Liu X, Tong Z. Asymptomatic Cases with SARS-CoV-2 Infection. J Med
496   Virol **2020**; n/a. Available at: https://doi.org/10.1002/jmv.25990.

497   17.   Arabi YM, Balkhy HH, Hayden FG, et al. Middle east respiratory syndrome. N Engl J Med
498   **2017**;

499   18.   Bordoni V, Sacchi A, Cimini E, et al. An inflammatory profile correlates with decreased
500   frequency of cytotoxic cells in COVID-19. Clin Infect Dis **2020**; Available at:
501   https://doi.org/10.1093/cid/ciaa577.

502   19.   Patel AA, Zhang Y, Fullerton JN, et al. The fate and lifespan of human monocyte subsets in
503   steady state and systemic inflammation. J Exp Med **2017**;

504   20.   Wildgruber M, Aschenbrenner T, Wendorff H, et al. The 'intermediate' CD14++ CD16+
505   monocyte subset increases in severe peripheral artery disease in humans. Sci Rep **2016**;

506   21.   Nockher WA, Scherberich JE. Expanded CD14+ CD16+ Monocyte subpopulation in patients
507   with acute and chronic infections undergoing hemodialysis. Infect Immun **1998**;

508   22.   Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical Monocytes in
509   Health and Disease. Annu Rev Immunol **2019**;

510   23.   Laidlaw BJ, Craft JE, Kaech SM. The multifaceted role of CD4+ T cells in CD8+ T cell
511   memory. Nat. Rev. Immunol. 2016;

512   24.   Victora GD, Schwickert TA, Fooksman DR, et al. Germinal center dynamics revealed by
513   multiphoton microscopy with a photoactivatable fluorescent reporter. Cell **2010**; 143:592–
514   605.

515   25.   Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of
516   2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet **2020**;

517   26.   Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-
518   19 patients. Cell. Mol. Immunol. 2020;

519   27.   Romero P, Zippelius A, Kurth I, et al. Four Functionally Distinct Populations of Human
520   Effector-Memory CD8 + T Lymphocytes . J Immunol **2007**;

28. Aranburu A, Piano Mortari E, Baban A, et al. Human B-cell memory is shaped by age- and
tissue-specific T-independent and GC-dependent events. Eur J Immunol **2017**; 47.

29. Victora GD, Nussenzweig MC. Germinal Centers. Annu Rev Immunol **2011**; 30:429–457.
Available at: http://www.annualreviews.org/doi/abs/10.1146/annurev-immunol-020711-
075032%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/22224772.

30. Aranburu A, Ceccarelli S, Giorda E, Lasorella R, Ballatore G, Carsetti R. TLR ligation
triggers somatic hypermutation in transitional B cells inducing the generation of IgM
memory B cells. J Immunol **2010**; 185:7293–7301.

31. Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM
memory B cells? Immunol. Lett. 2013; 152:114–120.

32. Yu H, Sun B, Fang Z, et al. Distinct features of SARS-CoV-2-specific IgA response in
COVID-19 patients. Eur Respir J **2020**;

33. Lam VC, Lanier LL. NK cells in host responses to viral infections. Curr. Opin. Immunol.
2017;

34. Vidal SM, Khakoo SI, Biron CA. Natural killer cell responses during viral infections:
Flexibility and conditioning of innate immunity by experience. Curr. Opin. Virol. 2011;

35. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: Development,
maturation, and clinical utilization. Front. Immunol. 2018;

36. Ochsenbein AF, Zinkernagel RM. Natural antibodies and complement link innate and
acquired immunity. Immunol. Today. 2000;

37. Ochsenbein AF, Fehr T, Lutz C, et al. Control of early viral and bacterial distribution and
disease by natural antibodies. Science (80-) **1999**;

38. Kang S, Brown HM, Hwang S. Direct antiviral mechanisms of interferon-gamma. Immune
Netw. 2018;

39. Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal
differentiation and production of natural antibodies. J Immunol **2008**; 180:800–808.

40. Rosado MM, Aranburu A, Capolunghi F, et al. From the fetal liver to spleen and gut: the
highway to natural antibody. Mucosal Immunol **2009**; 2:351–361. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/19421184.

41. Holodick NE, Rodríguez-Zhurbenko N, Hernández AM. Defining Natural Antibodies. Front
Immunol **2017**; 8:872.

42. Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal
antibodies cross-protective against H5N1 and H1N1 recovered from human IgM$^+$ memory B
cells. PLoS One **2008**; 3.

43. Carsetti R, Quintarelli C, Quinti I, et al. The immune system of children: the key to
understanding SARS-CoV-2 susceptibility? Lancet Child Adolesc Heal **2020**; 4:414–416.
Available at: https://doi.org/10.1016/S2352-4642(20)30135-8.

44. Selva KJ, Sandt CE van de, Lemke MM, et al. Distinct systems serology features in children,
elderly and COVID patients. medRxiv **2020**;

45. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for

monocytes and macrophages. Nat Rev Immunol **2020**; Available at:
https://doi.org/10.1038/s41577-020-0331-4.

46.   Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-
CoV-2 Drives Development of COVID-19. Cell **2020**;

47.   McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including
Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like
Disease. Autoimmun. Rev. 2020;

48.   Sanchez-Cerrillo I, Landete P, Aldave B, et al. Differential Redistribution of Activated
Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19.
medRxiv **2020**;

49.   Prilutskiy A, Kritselis M, Shevtsov A, et al. SARS-CoV-2 Infection Associated
Hemophagocytic Lymphohistiocytosis: An autopsy series with clinical and laboratory
correlation. medRxiv **2020**;

50.   Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science (80-) **2020**;

51.   Hayden A, Park S, Giustini D, Lee AYY, Chen LYC. Hemophagocytic syndromes (HPSs)
including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping
review. Blood Rev. 2016;

52.   Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary
Hemophagocytic Lymphohistiocytosis. N Engl J Med **2020**;

53.   Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of
Novel Coronavirus Pneumonia. Clin. Drug Investig. 2020;

54.   King A, Vail A, O'Leary C, et al. Anakinra in COVID-19: important considerations for
clinical trials. Lancet Rheumatol **2020**; Available at: https://doi.org/10.1016/S2665-
9913(20)30160-0.

55.   Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–
ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an
open-label, randomised, phase 2 trial. Lancet **2020**;

56.   Dahlke C, Heidepriem J, Kobbe R, et al. Distinct early IgA profile may determine severity of
COVID-19 symptoms: an immunological case series. medRxiv **2020**;

57.   Andreano E, Nicastri E, Paciello I, et al. Identification of neutralizing human monoclonal
antibodies from Italian Covid-19 convalescent patients. bioRxiv **2020**;

58.   He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro-inflammatory cytokines in
SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and
pathogenesis of SARS. J Pathol **2006**;

59.   Stavnezer J, Kang J. The Surprising Discovery That TGFβ Specifically Induces the IgA
Class Switch. J Immunol **2009**;

60.   Chen W. A potential treatment of COVID-19 with TGF-β blockade. Int. J. Biol. Sci. 2020;

61.   Ferner RE, Aronson JK. Remdesivir in covid-19. BMJ. 2020;

62.   Grimsholm O, Piano Mortari E, Davydov AN, et al. The Interplay between CD27dull and
CD27bright B Cells Ensures the Flexibility, Stability, and Resilience of Human B Cell

Memory. Cell Rep **2020**;

63.   Carsetti R, Di Sabatino A, Rosado MM, et al. Lack of Gut Secretory Immunoglobulin A in
Memory B-Cell Dysfunction-Associated Disorders: A Possible Gut-Spleen Axis. Front
Immunol **2020**;

64.   Seydoux E, Homad LJ, MacCamy AJ, et al. Analysis of a SARS-CoV-2 infected individual
reveals development of potent neutralizing antibodies to distinct epitopes with limited
somatic mutation. Immunity **2020**; Available at:
http://www.sciencedirect.com/science/article/pii/S1074761320302314.

65.   Pavlovich SS, Lovett SP, Koroleva G, et al. The Egyptian Rousette Genome Reveals
Unexpected Features of Bat Antiviral Immunity. Cell **2018**;

66.   Baker ML, Tachedjian M, Wang LF. Immunoglobulin heavy chain diversity in Pteropid bats:
Evidence for a diverse and highly specific antigen binding repertoire. Immunogenetics **2010**;

67.   Banerjee A, Baker ML, Kulcsar K, Misra V, Plowright R, Mossman K. Novel Insights Into
Immune Systems of Bats. Front. Immunol. 2020;

68.   chen meizhu, tu changli, Tan C, et al. Key to successful treatment of COVID-19: accurate
identification of severe risks and early intervention of disease progression. medRxiv **2020**;

69.   Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in
Wuhan, China. Clin Infect Dis **2020**;

70.   Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for Certainty on Covid-19
Antibody Tests — At What Cost? N Engl J Med 0:null. Available at:
https://doi.org/10.1056/NEJMp2017739.

Figure
625

Figure 1

626
627

Figure 1: (a) Flow-cytometry analysis of the monocyte to lymphocyte ratio (MLR) in the blood of three representative
patients with asymptomatic, mild and severe disease. The lympho-monocyte gate was designed based on physical
characteristics (FSC-A vs SSC-A). Lymphocytes were gated as FSC-A^{low} and CD3$^+$ or CD3$^-$ and monocytes as CD3$^-$
FSC-A^{high}. (b) Scatter plot depicts the MLR in the sixty-four adult patients enrolled in the study (contacts *n=28*;
asymptomatic *n=20*; mild *n=8*; severe *n=8*). (c) Gating strategy used to identify natural killer (NK) and monocytes
inside the CD3$^-$ cells in three representative patients with asymptomatic, mild and severe disease. NK cells were defined
as CD3$^-$CD7$^+$FSC-A^{low} and monocytes as CD3$^-$CD7$^-$FSC-A^{high}. (d) Heatmaps of the percentage of NK and monocytes
in contacts (indicated by the light green bar), asymptomatic (blue), mild (orange) and severe (red) patients. Percentage
levels are reported as differential expression of color. (e) Plots indicate the frequency of NK, monocytes and the
monocytes/NK ratio (MNKR) in our patients. (b and e) Midlines indicate mean. Statistical significances were
determined using unpaired, two-tailed Mann-Whitney *U*-tests. *p$\leq$0.05, **p$<$0.01, ***p$<$0.001.
639
640

641
642
643   **Figure 2:** (a) Plots indicate the frequency of NK, monocytes and MNKR ratio in all analyzed samples. We show here
644   all the results, including also those relative to multiple samples of the same patients collected at different time points.

(b) Heatmaps show the percentage of NK and monocytes in asymptomatic, mild and severe patients (Pt) measured at different time points. Percentage levels are reported as differential expression of red, blue and white. (c) Plot shows the percentage of NK cells in non-ICU ($n=43$) and ICU ($n=34$) patients. (d) Graphs show the evolution over time of NK cells percentage in patients with favorable and fatal outcome. (a and c) Midlines indicate mean. Statistical significances were determined using unpaired, two-tailed Mann-Whitney U-tests. *$p \leq 0.05$, **$p < 0.01$, ***$p < 0.001$.

Figure 3

Figure 3: (a) FACS plots depict the gating strategy to identify CD3$^+$, CD3$^+$CD4$^+$, CD3$^+$CD8$^+$ T cells in three representative patients (asymptomatic, mild and severe). HLA-DR expression in CD4$^+$ or CD8$^+$ T cells is shown in the relative plots. Frequency of HLA-DR$^+$ cells are reported in the plots. (b) Plots show the percentage of CD3$^+$, CD4$^+$, CD8$^+$ and HLA-DR$^+$ T cells as single value. Mean is shown as midline. Statistical significances were determined using unpaired, two-tailed Mann-Whitney U-tests. *$p \leq 0.05$, **$p < 0.01$, ***$p < 0.001$.

660   **Figure 4:** (a-b) Results obtained by the analysis of CD4+ (Plots a) and CD8+ T cells (Plots b) are separately shown.
661   Graphs show the percentage of *naïve* T cells (CD3+CCR7+CD45RA+) that either expressed or lack CD31 (CD31+ are

662   recent thymic emigrants and CD31$^-$ are revertant T cells). Effector memory T cells (CD3$^+$CCR7$^-$CD45RA$^-$) can be
663   separated in EM1, EM2, EM3 and EM4. TEMRA T cells are CD3$^+$CCR7$^-$CD45RA$^+$. Midlines indicate mean. Statistical
664   significances were determined using unpaired, two-tailed Mann-Whitney U-tests. *p$\leq$0.05, **p<0.01, ***p<0.001.
665

Figure 5: (a) Viable lymphocytes were gated and then selected as CD19+ B cells in three representative patients with
asymptomatic, mild and severe disease. The identification of the different B cell populations is shown in the empty

plots of the upper line. We identified transitional (CD24$^+$CD38^{++}), naïve (CD24$^+$CD27$^-$), memory (CD24$^+$CD27$^+$),
atypical MBCs (CD24$^-$CD38$^-$) and plasmablasts (CD24$^-$CD27^{++}CD38^{++}). In the CD27$^+$ memory B-cell population based
on IgM expression, we show IgM and switched (IgM$^-$) MBCs. MBCs were also gated as IgM$^+$, IgG$^+$ and IgG$^-$IgM$^-$
MBCs. (b) Plots indicates the percentage of B cells, MBCs and plasmablasts. In c the frequencies of IgM and switched
MBCs is show. Panel d we show the frequency of IgG$^+$, IgG$^-$IgM$^-$MBCs. The ratio between IgG$^+$ and IgG$^-$IgM$^-$ is also
shown. Midlines indicate mean. Statistical significances were determined using unpaired, two-tailed Mann-Whitney U-
tests. *p$\leq$0.05, **p<0.01, ***p<0.001.
677
678

679
Figure 6: (a) IgG and IgA specific for the S1 domain of the SARS-CoV-2 Spike protein were detected by an ELISA
method at different time points and concentrations are shown in arbitrary units (AU). Data relative to all samples are
shown. Midlines indicate mean. Statistical significances were determined using unpaired, two-tailed Mann-Whitney *U-*

tests. *p≤0.05, **p<0.01, ***p<0.001. (b-d) Graphs show the levels (AU) of IgA (solid line) and IgG (dashed line)
during the course of the disease in three asymptomatic (b), three mild (c) and three severe (d) disease patients. (e)
Kinetics of antibody titers in asymptomatic patients. Time is indicated in weeks from the first positive nasopharyngeal
swab. Empty circles represent patients of which we had only one sample and antibodies were undetectable.
687
688

693